InnoCare Pharma Limited
InnoCare Pharma Limited Fundamental Analysis
InnoCare Pharma Limited (9969.HK) shows moderate financial fundamentals with a PE ratio of 36.29, profit margin of 26.84%, and ROE of 9.08%. The company generates $2.0B in annual revenue with strong year-over-year growth of 36.68%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 72.1/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze 9969.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak9969.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate9969.HK shows balanced valuation metrics.
Growth Score
Excellent9969.HK delivers strong and consistent growth momentum.
Financial Health Score
Excellent9969.HK maintains a strong and stable balance sheet.
Profitability Score
Moderate9969.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 9969.HK Expensive or Cheap?
P/E Ratio
9969.HK trades at 36.29 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 9969.HK's PEG of 0.12 indicates potential undervaluation.
Price to Book
The market values InnoCare Pharma Limited at 2.97 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 43.35 times EBITDA. This signals the market has high growth expectations.
How Well Does 9969.HK Make Money?
Net Profit Margin
For every $100 in sales, InnoCare Pharma Limited keeps $26.84 as profit after all expenses.
Operating Margin
Core operations generate 22.98 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $9.08 in profit for every $100 of shareholder equity.
ROA
InnoCare Pharma Limited generates $5.84 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
InnoCare Pharma Limited generates limited operating cash flow of $123.64M, signaling weaker underlying cash strength.
Free Cash Flow
InnoCare Pharma Limited produces free cash flow of $64.07M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.04 in free cash annually.
FCF Yield
9969.HK converts 0.39% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
36.29
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.12
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.97
vs 25 benchmark
P/S Ratio
Price to sales ratio
8.26
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.21
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.83
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.09
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.06
vs 25 benchmark
How 9969.HK Stacks Against Its Sector Peers
| Metric | 9969.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 36.29 | 28.31 | Worse (Expensive) |
| ROE | 9.08% | 699.00% | Weak |
| Net Margin | 26.84% | -130884.00% (disorted) | Strong |
| Debt/Equity | 0.21 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 5.83 | 2775.16 | Strong Liquidity |
| ROA | 5.84% | -14469.00% (disorted) | Weak |
9969.HK outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews InnoCare Pharma Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
59821.56%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
84.75%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-239.29%
Industry Style: Defensive, Growth, Innovation
Declining